Citations

Clear

4610 citation(s) found for "Lu, Brian".

Long-Term Device Outcomes of Artificial Urinary Sphincter Reimplantation Following Prior Explantation for Erosion or Infection
Linder, Brian J. , Cógáin, Mitra de, Elliott, Daniel S. , de Cogain, Mitra, Linder, Brian J

Mayo Clinic

Journal of Urology | September 7, 2013 | Volume: 191 | Issue: 3 | Pages: 734-738

10.1016/j.juro.2013.08.089 | PMID 24018241 Get It

Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: Results of the National LymphoCare Study
Martin, Peter , Byrtek, Michelle, Dawson, Keith, Ziemiecki, Ryan , Friedberg, Jonathan W. , Cerhan, James R. , Flowers, Christopher R. , Link, Brian K. , Cerhan, James R , Link, Brian K

Mayo Clinic

Cancer | September 4, 2013 | Volume: 119 | Issue: 23 | Pages: 4129-4136

10.1002/cncr.28350 | PMID 24006156 Get It

BACKGROUNDDrug choice and delivered dose of treatment potentially influence outcome in patients treated for follicular lymphoma (FL). Historically, observational studies have evaluated drug choice. The National LymphoCare Study (NLCS) is a prospective, observational study of patients with FL who were enrolled at academic and community practice sites in the United States between 2004 and 2007. In the current study, the authors report on measures of delivered dose and its impact on outcomes for the most common first‐line regimens.METHODSAll evaluable patients with FL who were treated with initial rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R‐CHOP); rituximab plus cyclophosphamide, vincristine, and prednisone (R‐CVP); or rituximab plus a fludarabine‐containing regimen (R‐Flu) were included. Associations between baseline factors, choice of treatment, number of cycles received, completion of therapy, and patient outcomes were assessed.RESULTSA total of 646 patients received R‐CHOP, 297 received R‐CVP, and 222 received R‐Flu. Characteristics were similar between the 3 groups with the following exceptions. Patients receiving R‐CHOP were more often found to have grade 3 FL and patients receiving R‐CVP were older and had higher Follicular Lymphoma International Prognostic Index scores. The majority of patients (80%) received ≥ 5 cycles of treatment. Toxicity, but not disease progression, was commonly cited as the reason for the early discontinuation of treatment (51% vs 6%). Time to retreatment was shorter for patients receiving ≤ 4 cycles, regardless of the treatment regimen used. The number of cycles was associated with overall survival, progression‐free survival, and lymphoma‐related mortality for patients receiving R‐CVP.CONCLUSIONSThe majority of patients with FL receiving chemoimmunotherapy in the NLCS completed ≥ 5 cycles of treatment. Strategies to improve dose delivery appear unlikely to impact outcomes, except possibly in patients receiving R‐CVP. Although early treatment discontinuation appears to be associated with survival, this analysis does not implicate causality. Cancer 2013;119:4129–4136. © 2013 American Cancer Society.
Clinical Characteristics of Children With Juvenile Dermatomyositis: The Childhood Arthritis and Rheumatology Research Alliance Registry
Robinson, Angela Byun , Hoeltzel, Mark F., Wahezi, Dawn M. , Becker, Mara L. , Kessler, Elizabeth A., Schmeling, Heinrike , Carrasco, Ruy , Huber, Adam M. , Reed, Ann M., Investigators, the Juvenile Myositis CARRA Subgroup, for the CARRA Registry, Feldman, Brian Michael , Investigators, the Juvenile Myositis CARRA Subgroup, for the CARRA Registry

Mayo Clinic

Arthritis Care & Research | August 27, 2013 | Volume: 66 | Issue: 3 | Pages: 404-410

10.1002/acr.22142 | PMID 23983017 Get It

Objective To investigate aspects of juvenile dermatomyositis (DM), including disease characteristics and treatment, through a national multicenter registry. Methods Subjects meeting the modified Bohan and Peter criteria for definite juvenile DM were analyzed from the cross‐sectional Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry between 2010 and 2012 from 55 US pediatric rheumatology centers. Demographics, disease characteristics, diagnostic assessments, and medication exposure data were collected at enrollment. Results A total of 384 subjects met the criteria for analysis. At enrollment, the median Childhood Myositis Assessment Scale score was 51 (interquartile range [IQR] 46–52), the median Childhood Health Assessment Questionnaire score was 0 (IQR 0–0.5), and the median physician and subject global assessment scores were 1 (IQR 0–2) and 1 (IQR 0–3), respectively, out of a maximum of 10. Of the diagnostic assessments, magnetic resonance imaging was more likely than electromyography or muscle biopsy to show abnormalities. A total of 329 subjects had ≥2 diagnostic studies performed, and >34% of these subjects reported ≥1 negative study. Ninety‐five percent had been treated with corticosteroids and 92% with methotrexate, suggesting that these medications were almost universally prescribed for juvenile DM in the US. Conclusion In 2 years, the ongoing CARRA Registry has collected clinical data on 384 children with juvenile DM and has the potential to become one of the largest juvenile DM cohorts in the world. More research is needed about prognostic factors in juvenile DM, and differences in therapy based on manifestations of disease need to be explored by practitioners. This registry provides the infrastructure needed to advance clinical and translational research and represents a major step toward improving outcomes of children with juvenile DM.
Comparison of Outcomes After Fluorouracil-Based Adjuvant Therapy for Stages II and III Colon Cancer Between 1978 to 1995 and 1996 to 2007: Evidence of Stage Migration From the ACCENT Database
Shi, Qian , André, Thierry , Yothers, Greg , Bot, Brian M. , Haller, Daniel G. , Twelves, Chris , Benedetti, Jacqueline, Grothey, Axel , Hamilton, Stanley R. , Cutsem, Eric Van , O’Connell, Michael J. , Sargent, Daniel J. , André, Thierry , Shi, Qian , Yothers, Greg

Mayo Clinic

Journal of Clinical Oncology | August 27, 2013 | Volume: 31 | Issue: 29 | Pages: 3656-3663

10.1200/jco.2013.49.4344 | PMID 23980089 Get It

Purpose With improved patient care, better diagnosis, and more treatment options after tumor recurrence, outcomes after fluorouracil (FU) -based treatment are expected to have improved over time in early-stage colon cancer. Data from 18,449 patients enrolled onto 21 phase III trials conducted from 1978 to 2002 were evaluated for potential differences in time to recurrence (TTR), time from recurrence to death (TRD), and overall survival (OS) with regard to FU-based adjuvant regimens. Methods Trials were predefined as old versus newer era using initial accrual before or after 1995. Outcomes were compared between patients enrolled onto old- or newer-era trials, stratified by stage. Results Within the first 3 years, recurrence rates were lower in newer- versus old-era trials for patients with stage II disease, with no differences among those with stage III disease. Both TRD and OS were significantly longer in newer-era trials overall and within each stage. The lymph node (LN) ratio (ie, number of positive nodes divided by total nodes harvested) in those with stage III disease declined over time. TTR improved slightly, with larger number of LNs examined in both stages. Conclusion Improved TRD in newer trials supports the premise that more aggressive intervention (oxaliplatin- and irinotecan-based chemotherapy and/or surgery for recurrent disease) improves OS for patients previously treated in the adjuvant setting. Lower recurrence rates with identical treatments in those with stage II disease enrolled onto newer-era trials reflect stage migration over time, calling into question historical data related to the benefit of FU-based adjuvant therapy in such patients.
Letter: East-West differences in the economic impact of functional dyspepsia - authors’ reply
Lacy, Brian E. , Crowell, Michael D. , Lacy, Brian E. , Talley, Nicholas J. , Crowell, Michael D

Mayo Clinic

Alimentary Pharmacology & Therapeutics | August 22, 2013 | Volume: 38 | Issue: 6 | Pages: 656-656

10.1111/apt.12448 | PMID 23964736 Get It

Search for genetic modifiers of IRF6 and genotype–phenotype correlations in Van der Woude and popliteal pterygium syndromes
Leslie, Elizabeth J. , Mancuso, Jennifer L., Schutte, Brian C. , Cooper, Margaret E., Durda, Kate, L’Heureux, Jamie, Zucchero, Theresa M., Marazita, Mary L. , Murray, Jeffrey C.

Mayo Clinic

American Journal of Medical Genetics Part A | August 15, 2013 | Volume: 161 | Issue: 10 | Pages: 2535-2544

10.1002/ajmg.a.36133 | PMID 23949966 Get It

ABSTRACTVan der Woude syndrome is the most common form of syndromic orofacial clefting, accounting for 1–2% of all patients with cleft lip and/or cleft palate. Van der Woude and popliteal pterygium syndromes are caused by mutations in IRF6, but phenotypic variability within and among families with either syndrome suggests that other genetic factors contribute to the phenotypes. The aim of this study was to identify common variants acting as genetic modifiers of IRF6 as well as genotype–phenotype correlations based on mutation type and location. We identified an association between mutations in the DNA‐binding domain of IRF6 and limb defects (including pterygia). Although we did not detect formally significant associations with the genes tested, borderline associations suggest several genes that could modify the VWS phenotype, including FOXE1, TGFB3, and TFAP2A. Some of these genes are hypothesized to be part of the IRF6 gene regulatory network and may suggest additional genes for future study when larger sample sizes are also available. We also show that families with the Van de Woude phenotype but in whom no mutations have been identified have a lower frequency of cleft lip, suggesting there may be locus and/or mutation class differences in Van de Woude syndrome. © 2013 Wiley Periodicals, Inc.
Macrophage-secreted cytokines drive pancreatic acinar-to-ductal metaplasia through NF-κB and MMPs
Döppler, Heike, Necela, Brian M. , Krishna, Murli , Raimondo, Massimo , Störz, Peter , Liou, Geou‐Yarh , Crawford, Howard C.

Mayo Clinic

Journal of Cell Biology | August 5, 2013 | Volume: 202 | Issue: 3 | Pages: 563-577

10.1083/jcb.201301001 | PMID 23918941 Get It

In response to inflammation, pancreatic acinar cells can undergo acinar-to-ductal metaplasia (ADM), a reprogramming event that induces transdifferentiation to a ductlike phenotype and, in the context of additional oncogenic stimulation, contributes to development of pancreatic cancer. The signaling mechanisms underlying pancreatitis-inducing ADM are largely undefined. Our results provide evidence that macrophages infiltrating the pancreas drive this transdifferentiation process. We identify the macrophage-secreted inflammatory cytokines RANTES and tumor necrosis factor α (TNF) as mediators of such signaling. Both RANTES and TNF induce ADM through activation of nuclear factor κB and its target genes involved in regulating survival, proliferation, and degradation of extracellular matrix. In particular, we identify matrix metalloproteinases (MMPs) as targets that drive ADM and provide in vivo data suggesting that MMP inhibitors may be efficiently applied to block pancreatitis-induced ADM in therapy.
Population‐specific frequencies for LRRK2 susceptibility variants in the genetic epidemiology of Parkinson's disease (GEO‐PD) consortium
Soto‐Ortolaza, Alexandra I., Aasly, Jan , Abahuni, Nadine, Annesi, Grazia , Bacon, Justin A., Bardien, Soraya , Bozi, Maria , Brice, Alexis , Brighina, Laura , Carr, Jonathan , Chartier‐Harlin, Marie‐Christine , Dardiotis, Efthimios , Dickson, Dennis W. , Diehl, Nancy N. , Ferrarese, Carlo , Fiske, Brian , Gibson, Rachel A. , Hattori, Nobutaka , Ioannidis, John P. A. , Boczarska‐Jedynak, Magdalena , Jasińska‐Myga, Barbara, Jeon, Beom S., Kim, Yun Joong , Klein, Christine , Krüger, Rejko , Kyratzi, Elli, Lesage, Suzanne , Lin, Chin‐Hsien , Lynch, Timothy , Maraganore, Demetrius M. , Mellick, George D. , Mutez, Eugénie , Opala, Grzegorz, Park, Sung Sup , Petrucci, Simona , Puschmann, Andreas , Quattrone, Aldo , Sharma, Manu , Silburn, Peter A., Sohn, Young H. , Tadić, Vera, Theuns, Jessie , Tomiyama, Hiroyuki , Uitti, Ryan J. , Valente, Enza Maria , Broeckhoven, Christine Van , Loo, Simone van de, Vassilatis, Demetrios K. , Vilariño‐Güell, Carles , White, Linda R., Wirdefeldt, Karin , Wu, Ruey‐Meei , Hentati, Fayçal, Farrer, Matthew J. , Ross, Owen A. , Soto‐Beasley, Alexandra I. , Heckman, Michael G. , Elbaz, Alexis , Gibson, Jonathan M. , Hadjigeorgiou, Georgios M. , Nilsson, Christer C. , Stefanis, Leonidas , Wszołek, Zbigniew K. , Dickson, Dennis W , Ross, Owen A , Puschmann, Andreas , Klein, Christine , Bardien, Soraya , Mutez, Eugénie , Valente, Enza Maria , Ioannidis, John P A , Beasley, Alexandra I , Carr, Jonathan , Brice, Alexis , Lin, Chin-Hsien , Wu, Ruey-Meei

Mayo Clinic

Movement Disorders | August 2, 2013 | Volume: 28 | Issue: 12 | Pages: 1740-1744

10.1002/mds.25600 | PMID 23913756 Get It

ABSTRACTBackgroundVariants within the leucine‐rich repeat kinase 2 gene are recognized as the most frequent genetic cause of Parkinson's disease. Leucine‐rich repeat kinase 2 variation related to disease susceptibility displays many features that reflect the nature of complex, late‐onset sporadic disorders like Parkinson's disease.MethodsThe Genetic Epidemiology of Parkinson's Disease Consortium recently performed the largest genetic association study for variants in the leucine‐rich repeat kinase 2 gene across 23 different sites in 15 countries.ResultsHerein, we detail the allele frequencies for the novel risk factors (p.A419V and p.M1646T) and the protective haplotype (p.N551K‐R1398H‐K1423K) nominated in the original publication. Simple population allele frequencies not only can provide insight into the clinical relevance of specific variants but also can help genetically define patient groups.ConclusionsEstablishing individual patient‐based genomic susceptibility profiles that incorporate both risk factors and protective factors will determine future diagnostic and treatment strategies. © 2013 International Parkinson and Movement Disorder Society
Safety and efficacy of upfront plerixafor + G‐CSF versus placebo + G‐CSF for mobilization of CD34+ hematopoietic progenitor cells in patients ≥60 and
Micallef, Ivana N. , Stiff, Patrick J. , Stadtmauer, Edward A. , Bolwell, Brian J., Nademanee, Auayporn, Partisano, Angela M., Marulkar, Sachin, Maziarz, Richard Thomas , DiPersio, John F.

Mayo Clinic

American Journal of Hematology | August 1, 2013 | Volume: 88 | Issue: 12 | Pages: 1017-1023

10.1002/ajh.23561 | PMID 23907769 Get It

The efficacy and safety of plerixafor + G‐CSF in enhancing hematopoietic stem cell mobilization and collection has been demonstrated in two phase III studies involving patients with NHL or MM. In these pivotal studies, plerixafor + G‐CSF significantly increased the proportion of patients achieving target stem cell yields, compared to placebo + G‐CSF. In this analysis, we compare the efficacy and safety of plerixafor + G‐CSF versus placebo + G‐CSF in patients enrolled in the two phase III studies, stratified by age: ≥60 years of age and <60 years of age. The proportion of older patients who achieved target stem cell yields was significantly higher in the plerixafor group than in placebo group (NHL: 50.9 vs. 25.4%, P < 0.001; MM: 69.6 vs. 23.7%, P < 0.001). In this older cohort, the median times to neutrophil and to platelet engraftment following autologous stem cell transplant were comparable between the plerixafor and placebo groups. Similar efficacy findings were observed in the younger age group. The most common adverse events (all grades) reported among older patients in the plerixafor group included diarrhea (41.3%), nausea (38.9%), fatigue (30.2%), and injection‐site reaction (29.4%). The frequency of adverse events was similar between the older and the younger age groups. Taken together, our subanalysis demonstrate that plerixafor + G‐CSF can be safely and effectively used in adult patients of all ages, including those ≥60 years, to support optimal stem cell mobilization for autologous stem cell transplantation. Am. J. Hematol. 88:1017–1023, 2013. © 2013 Wiley Periodicals, Inc.